Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
1. Beam reports promising Phase 1/2 trial data for BEAM-302 treatment. 2. Safety and efficacy data show durable correction of AAT deficiency. 3. Company plans further trials and data presentations by 2025. 4. AAT deficiency can lead to serious lung and liver diseases. 5. Stock is currently down 3.44%, priced at $27.50.